Overall, statistical differences in antibody titers against EBNA1 (AA386-405) and GlialCAM (AA370-389) were observed at the group level, with only a subset of MS patients exhibited significantly elevated antibody titers (36). This evidence concerns the gene HEPACAM and myeloid sarcoma.